ACS (excluding AMI): 2 trials - CURE - CURRENT OASIS 7 (clopidogrel)
| clopidogrel + aspirin vs aspirin | No demonstrated result Major bleeding by 38% (harmful effect) suggested cardiovascular events by 18% (not demonstrated) suggested myocardial infarction (fatal and non fatal) by 22% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| all cause death, MI, stroke | no data | | refractory ischemia | 0.93 [0.83 1.05] | p=1.00 | 0 | 12562 | 1 | CURE, | | cardiovascular events | 0.82 [0.73 0.91] | p=0.04 | 0 | 12562 | 1 | CURE, | | myocardial infarction (fatal and non fatal) | 0.78 [0.67 0.90] | p=0.04 | 0 | 12562 | 1 | CURE, | | stroke (fatal and non fatal) | 0.87 [0.64 1.18] | p=1.00 | 0 | 12562 | 1 | CURE, | | ischemic stroke | no data | | Vascular death | 0.93 [0.79 1.09] | p=1.00 | 0 | 12562 | 1 | CURE, | | Non vascular death | 0.92 [0.60 1.40] | p=1.00 | 0 | 12562 | 1 | CURE, | | Non fatal MI | no data | | Revascularization | no data | | All cause death | no data | | Non fatal stroke | no data | | fatal bleeding | 0.74 [0.34 1.61] | p=1.00 | 0 | 12562 | 1 | CURE, | | Bleeding | no data | | Major bleeding | 1.38 [1.13 1.68] | p=0.04 | 0 | 12562 | 1 | CURE, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| clopidogrel high-dose regimen vs clopidogrel standard-dose | No demonstrated result Major bleeding by 24% (harmful effect) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| all cause death, MI, stroke | no data | | refractory ischemia | no data | | cardiovascular events | 0.94 [0.83 1.06] | p=1.00 | 0 | 25086 | 1 | CURRENT OASIS 7 (clopidogrel), | | myocardial infarction (fatal and non fatal) | 0.86 [0.72 1.02] | p=1.00 | 0 | 25086 | 1 | CURRENT OASIS 7 (clopidogrel), | | stroke (fatal and non fatal) | 0.99 [0.70 1.40] | p=1.00 | 0 | 25086 | 1 | CURRENT OASIS 7 (clopidogrel), | | ischemic stroke | no data | | Vascular death | 0.95 [0.81 1.13] | p=1.00 | 0 | 25086 | 1 | CURRENT OASIS 7 (clopidogrel), | | Non vascular death | no data | | Non fatal MI | no data | | Revascularization | no data | | All cause death | 0.96 [0.82 1.13] | p=1.00 | 0 | 25086 | 1 | CURRENT OASIS 7 (clopidogrel), | | Non fatal stroke | no data | | fatal bleeding | 1.07 [0.53 2.17] | p=1.00 | 0 | 25086 | 1 | CURRENT OASIS 7 (clopidogrel), | | Bleeding | no data | | Major bleeding | 1.24 [1.05 1.46] | p=0.04 | 0 | 25086 | 1 | CURRENT OASIS 7 (clopidogrel), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 2 trials - CURE - CURRENT OASIS 7 (clopidogrel)
| clopidogrel + aspirin vs aspirin | No demonstrated result Major bleeding by 38% (harmful effect) suggested cardiovascular events by 18% (not demonstrated) suggested myocardial infarction (fatal and non fatal) by 22% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| all cause death, MI, stroke | no data | | refractory ischemia | 0.93 [0.83 1.05] | p=1.00 | 0 | 12562 | 1 | CURE, | | cardiovascular events | 0.82 [0.73 0.91] | p=0.04 | 0 | 12562 | 1 | CURE, | | myocardial infarction (fatal and non fatal) | 0.78 [0.67 0.90] | p=0.04 | 0 | 12562 | 1 | CURE, | | stroke (fatal and non fatal) | 0.87 [0.64 1.18] | p=1.00 | 0 | 12562 | 1 | CURE, | | ischemic stroke | no data | | Vascular death | 0.93 [0.79 1.09] | p=1.00 | 0 | 12562 | 1 | CURE, | | Non vascular death | 0.92 [0.60 1.40] | p=1.00 | 0 | 12562 | 1 | CURE, | | Non fatal MI | no data | | Revascularization | no data | | All cause death | no data | | Non fatal stroke | no data | | fatal bleeding | 0.74 [0.34 1.61] | p=1.00 | 0 | 12562 | 1 | CURE, | | Bleeding | no data | | Major bleeding | 1.38 [1.13 1.68] | p=0.04 | 0 | 12562 | 1 | CURE, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| clopidogrel high-dose regimen vs clopidogrel standard-dose | No demonstrated result Major bleeding by 24% (harmful effect) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| all cause death, MI, stroke | no data | | refractory ischemia | no data | | cardiovascular events | 0.94 [0.83 1.06] | p=1.00 | 0 | 25086 | 1 | CURRENT OASIS 7 (clopidogrel), | | myocardial infarction (fatal and non fatal) | 0.86 [0.72 1.02] | p=1.00 | 0 | 25086 | 1 | CURRENT OASIS 7 (clopidogrel), | | stroke (fatal and non fatal) | 0.99 [0.70 1.40] | p=1.00 | 0 | 25086 | 1 | CURRENT OASIS 7 (clopidogrel), | | ischemic stroke | no data | | Vascular death | 0.95 [0.81 1.13] | p=1.00 | 0 | 25086 | 1 | CURRENT OASIS 7 (clopidogrel), | | Non vascular death | no data | | Non fatal MI | no data | | Revascularization | no data | | All cause death | 0.96 [0.82 1.13] | p=1.00 | 0 | 25086 | 1 | CURRENT OASIS 7 (clopidogrel), | | Non fatal stroke | no data | | fatal bleeding | 1.07 [0.53 2.17] | p=1.00 | 0 | 25086 | 1 | CURRENT OASIS 7 (clopidogrel), | | Bleeding | no data | | Major bleeding | 1.24 [1.05 1.46] | p=0.04 | 0 | 25086 | 1 | CURRENT OASIS 7 (clopidogrel), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with scheduled percutaneous coronary intervention : 1 trials - CURRENT OASIS 7 (clopidogrel)
| clopidogrel high-dose regimen vs clopidogrel standard-dose | No demonstrated result Major bleeding by 24% (harmful effect) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| all cause death, MI, stroke | no data | | refractory ischemia | no data | | cardiovascular events | 0.94 [0.83 1.06] | p=1.00 | 0 | 25086 | 1 | CURRENT OASIS 7 (clopidogrel), | | myocardial infarction (fatal and non fatal) | 0.86 [0.72 1.02] | p=1.00 | 0 | 25086 | 1 | CURRENT OASIS 7 (clopidogrel), | | stroke (fatal and non fatal) | 0.99 [0.70 1.40] | p=1.00 | 0 | 25086 | 1 | CURRENT OASIS 7 (clopidogrel), | | ischemic stroke | no data | | Vascular death | 0.95 [0.81 1.13] | p=1.00 | 0 | 25086 | 1 | CURRENT OASIS 7 (clopidogrel), | | Non vascular death | no data | | Non fatal MI | no data | | Revascularization | no data | | All cause death | 0.96 [0.82 1.13] | p=1.00 | 0 | 25086 | 1 | CURRENT OASIS 7 (clopidogrel), | | Non fatal stroke | no data | | fatal bleeding | 1.07 [0.53 2.17] | p=1.00 | 0 | 25086 | 1 | CURRENT OASIS 7 (clopidogrel), | | Bleeding | no data | | Major bleeding | 1.24 [1.05 1.46] | p=0.04 | 0 | 25086 | 1 | CURRENT OASIS 7 (clopidogrel), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
PCI sub group: 1 trials - CURE (PCI sub study)
| clopidogrel vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| all cause death, MI, stroke | no data | | Urgent target-vessel revascularization | no data | | Major or minor TIMI bleeding | no data | | death, MI, unplanned revascularization | no data | | cardiovascular events | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | Stent thrombosis (any, end of follow up) | no data | | All cause death | no data | | major bleeding TIMI | no data | | TIMI minor bleeding | no data | | Major bleeding | no data | | ischemic events + bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
STEMI patients: 2 trials - COMMIT - CLARITY-TIMI 28
| clopidogrel vs placebo | No demonstrated result suggested cardiovascular events by 8% (not demonstrated) suggested Non fatal MI by 18% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.92 [0.86 0.97] | p=0.04 | 0 | 45852 | 1 | COMMIT, | | Cardiovascular death | no data | | Non fatal MI | 0.82 [0.69 0.96] | p=0.04 | 0 | 45852 | 1 | COMMIT, | | non cardiovascular death | no data | | Non fatal stroke | 0.89 [0.70 1.13] | p=1.00 | 0 | 45852 | 1 | COMMIT, | | Major bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 2 trials - COMMIT - CLARITY-TIMI 28
| clopidogrel vs placebo | No demonstrated result suggested cardiovascular events by 8% (not demonstrated) suggested Non fatal MI by 18% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.92 [0.86 0.97] | p=0.04 | 0 | 45852 | 1 | COMMIT, | | Cardiovascular death | no data | | Non fatal MI | 0.82 [0.69 0.96] | p=0.04 | 0 | 45852 | 1 | COMMIT, | | non cardiovascular death | no data | | Non fatal stroke | 0.89 [0.70 1.13] | p=1.00 | 0 | 45852 | 1 | COMMIT, | | Major bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Primary prevention of thromboembolic events: 2 trials - ACTIVE W - ACTIVE A
| aspirin + clopidogrel vs anticoagulant | No demonstrated result suggested thrombo-embolic event (cerebral or systemic) by 43% (not demonstrated) suggested ischemic stroke by 117% (not demonstrated) suggested Haemmorhagic stroke by 66% (not demonstrated) suggested stroke (fatal and non fatal) by 71% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| systemic thrombo-embolic complication | no data | | thrombo-embolic event (cerebral or systemic) | 1.43 [1.17 1.76] | p=0.04 | 0 | 6706 | 1 | ACTIVE W, | | TE event or ischemic stroke or systemic embolism | no data | | ischemic stroke | 2.17 [1.50 3.13] | p=0.04 | 0 | 6706 | 1 | ACTIVE W, | | Lifethreatening major bleeding | no data | | Non-lifethreatening major bleeding | no data | | Gastrointestinal major bleeding | no data | | major or clinically relevant non-major bleeding | no data | | hypertransaminasemia | no data | | Major bleeding | 1.10 [0.82 1.46] | p=1.00 | 0 | 6706 | 1 | ACTIVE W, | | Haemmorhagic stroke | 0.34 [0.12 0.93] | p=0.04 | 0 | 6706 | 1 | ACTIVE W, | | Fatal bleeding | 0.64 [0.25 1.66] | p=1.00 | 0 | 6706 | 1 | ACTIVE W, | | Cardiovascular death | 1.14 [0.88 1.49] | p=1.00 | 0 | 6706 | 1 | ACTIVE W, | | stroke (fatal and non fatal) | 1.71 [1.24 2.37] | p=0.04 | 0 | 6706 | 1 | ACTIVE W, | | Coronary event | no data | | All cause death | 1.02 [0.81 1.27] | p=1.00 | 0 | 6706 | 1 | ACTIVE W, | | Fatal stroke | 0.94 [0.45 1.96] | p=1.00 | 0 | 6706 | 1 | ACTIVE W, | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| aspirin + clopidogrel vs aspirin | No demonstrated result Major bleeding by 57% (harmful effect) suggested ischemic stroke by 31% (not demonstrated) suggested stroke (fatal and non fatal) by 27% (not demonstrated) suggested Fatal stroke by 28% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| systemic thrombo-embolic complication | no data | | thrombo-embolic event (cerebral or systemic) | 0.90 [0.81 1.00] | p=1.00 | 0 | 7554 | 1 | ACTIVE A, | | TE event or ischemic stroke or systemic embolism | NaN [NaN NaN] | p=1.00 | 0 | 7554 | 1 | ACTIVE A, | | ischemic stroke | 0.69 [0.58 0.82] | p=0.04 | 0 | 7554 | 1 | ACTIVE A, | | Lifethreatening major bleeding | no data | | Non-lifethreatening major bleeding | no data | | Gastrointestinal major bleeding | no data | | major or clinically relevant non-major bleeding | no data | | hypertransaminasemia | no data | | Major bleeding | 1.57 [1.29 1.91] | p=0.04 | 0 | 7554 | 1 | ACTIVE A, | | Haemmorhagic stroke | 1.37 [0.79 2.37] | p=1.00 | 0 | 7554 | 1 | ACTIVE A, | | Fatal bleeding | 1.56 [0.96 2.53] | p=1.00 | 0 | 7554 | 1 | ACTIVE A, | | Cardiovascular death | 1.00 [0.89 1.14] | p=1.00 | 0 | 7554 | 1 | ACTIVE A, | | stroke (fatal and non fatal) | 0.73 [0.62 0.85] | p=0.04 | 0 | 7554 | 1 | ACTIVE A, | | Coronary event | no data | | All cause death | 0.98 [0.88 1.10] | p=1.00 | 0 | 7554 | 1 | ACTIVE A, | | Fatal stroke | 0.72 [0.59 0.88] | p=0.04 | 0 | 7554 | 1 | ACTIVE A, | | Non fatal stroke | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - CASCADE
| clopidogrel+aspirin vs aspirin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | no data | | Cardiovascular death | no data | | Non vascular death | no data | | Non fatal MI | no data | | Non fatal stroke | no data | | Major bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 2 trials - CAPRIE - CHARISMA
| clopidogrel vs aspirin | No demonstrated result suggested Non fatal MI by 16% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.92 [0.84 1.01] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Cardiovascular death | 0.92 [0.80 1.07] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Non fatal MI | 0.84 [0.70 1.00] | p=0.04 | 0 | 19185 | 1 | CAPRIE, | | All cause death | 0.98 [0.87 1.10] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Non fatal stroke | 0.94 [0.82 1.08] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Major bleeding | 0.88 [0.70 1.12] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Fatal bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| clopidogrel vs placebo (on top aspirin) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.93 [0.82 1.05] | p=1.00 | 0 | 15603 | 1 | CHARISMA, | | Cardiovascular death | 1.04 [0.86 1.25] | p=1.00 | 0 | 15603 | 1 | CHARISMA, | | Non fatal MI | 0.92 [0.74 1.16] | p=1.00 | 0 | 15603 | 1 | CHARISMA, | | All cause death | 0.99 [0.86 1.15] | p=1.00 | 0 | 15603 | 1 | CHARISMA, | | Non fatal stroke | 0.81 [0.65 1.00] | p=1.00 | 0 | 15603 | 1 | CHARISMA, | | Major bleeding | 1.25 [0.96 1.62] | p=1.00 | 0 | 15603 | 1 | CHARISMA, | | Fatal bleeding | 1.53 [0.83 2.82] | p=1.00 | 0 | 15603 | 1 | CHARISMA, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Secondary prevention in patients with CAD: 3 trials - CAPRIE - CHARISMA - ASCET
| clopidogrel vs aspirin | No demonstrated result suggested Non fatal MI by 16% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.92 [0.84 1.01] | p=1.00 | 0 | 20186 | 2 | CAPRIE,ASCET, | | Cardiovascular death | 0.92 [0.80 1.07] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Non vascular death | no data | | Non fatal MI | 0.84 [0.70 1.00] | p=0.04 | 0 | 19185 | 1 | CAPRIE, | | All cause death | 0.98 [0.87 1.10] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Non fatal stroke | 0.94 [0.82 1.08] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Major bleeding | 0.88 [0.70 1.12] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Fatal bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| clopidogrel vs placebo (on top aspirin) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.93 [0.82 1.05] | p=1.00 | 0 | 15603 | 1 | CHARISMA, | | Cardiovascular death | 1.04 [0.86 1.25] | p=1.00 | 0 | 15603 | 1 | CHARISMA, | | Non fatal MI | 0.92 [0.74 1.16] | p=1.00 | 0 | 15603 | 1 | CHARISMA, | | All cause death | 0.99 [0.86 1.15] | p=1.00 | 0 | 15603 | 1 | CHARISMA, | | Non fatal stroke | 0.81 [0.65 1.00] | p=1.00 | 0 | 15603 | 1 | CHARISMA, | | Major bleeding | 1.25 [0.96 1.62] | p=1.00 | 0 | 15603 | 1 | CHARISMA, | | Fatal bleeding | 1.53 [0.83 2.82] | p=1.00 | 0 | 15603 | 1 | CHARISMA, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Secondary prevention: 2 trials - CAPRIE - CHARISMA
| clopidogrel vs aspirin | No demonstrated result suggested Non fatal MI by 16% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.92 [0.84 1.01] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Cardiovascular death | 0.92 [0.80 1.07] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Non fatal MI | 0.84 [0.70 1.00] | p=0.04 | 0 | 19185 | 1 | CAPRIE, | | All cause death | 0.98 [0.87 1.10] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Non fatal stroke | 0.94 [0.82 1.08] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Major bleeding | 0.88 [0.70 1.12] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Fatal bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| clopidogrel vs placebo (on top aspirin) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.93 [0.82 1.05] | p=1.00 | 0 | 15603 | 1 | CHARISMA, | | Cardiovascular death | 1.04 [0.86 1.25] | p=1.00 | 0 | 15603 | 1 | CHARISMA, | | Non fatal MI | 0.92 [0.74 1.16] | p=1.00 | 0 | 15603 | 1 | CHARISMA, | | All cause death | 0.99 [0.86 1.15] | p=1.00 | 0 | 15603 | 1 | CHARISMA, | | Non fatal stroke | 0.81 [0.65 1.00] | p=1.00 | 0 | 15603 | 1 | CHARISMA, | | Major bleeding | 1.25 [0.96 1.62] | p=1.00 | 0 | 15603 | 1 | CHARISMA, | | Fatal bleeding | 1.53 [0.83 2.82] | p=1.00 | 0 | 15603 | 1 | CHARISMA, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Secondary prevention in patients with intermittent claudication: 2 trials - CAPRIE (PAD subgroup) - CAPRIE
| clopidogrel vs aspirin | No demonstrated result suggested myocardial infarction (fatal and non fatal) by 37% (not demonstrated) suggested Fatal MI by 38% (not demonstrated) suggested Non fatal MI by 18% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Amputation | no data | | cardiovascular events | 0.92 [0.84 1.01] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Cardiovascular death | 0.92 [0.80 1.07] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | myocardial infarction (fatal and non fatal) | 0.63 [0.46 0.86] | p=0.04 | 0 | 6452 | 1 | CAPRIE (PAD subgroup), | | Vascular death | no data | | Fatal MI | 0.62 [0.43 0.88] | p=0.04 | 0 | 6452 | 1 | CAPRIE (PAD subgroup), | | Non fatal MI | 0.82 [0.69 0.97] | p=0.04 | 0 | 25637 | 2 | CAPRIE (PAD subgroup),CAPRIE, | | Vascular events | no data | | All cause death | 0.95 [0.85 1.06] | p=1.00 | 0 | 25637 | 2 | CAPRIE (PAD subgroup),CAPRIE, | | Fatal stroke | 0.95 [0.68 1.32] | p=1.00 | 0 | 6452 | 1 | CAPRIE (PAD subgroup), | | Non fatal stroke | 0.95 [0.83 1.09] | p=1.00 | 0 | 25637 | 2 | CAPRIE (PAD subgroup),CAPRIE, | | Major bleeding | 0.88 [0.70 1.12] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Fatal bleeding | no data | | Non cerebral major bleeding | no data | | Fatal bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 2 trials - CAPRIE - ASCET
| clopidogrel vs aspirin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.90 [0.60 1.35] | p=1.00 | 0 | 1001 | 1 | ASCET, | | Cardiovascular death | no data | | Coronary event | no data | | Non vascular death | no data | | Fatal MI | 0.71 [0.50 1.00] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Non fatal MI | 0.85 [0.71 1.00] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | All cause death | 0.98 [0.87 1.10] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Non fatal stroke | no data | | Major bleeding | no data | | Adverse events | no data | | Major bleeding | no data | | stroke (fatal and non fatal) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - WATCH (clopidogrel vs aspirin)
| clopidogrel vs aspirin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| exacerbation of heart failure | no data | | All-cause hospitalisation | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | Serious adverse event | no data | | All cause death | no data | | Major bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 6 trials - Müller - CLASSICS - TOPPS - Piamsomboon - GRAVITAS - REAL-LATE, ZEST-LATE
| clopidogrel + aspirin vs ticlopidine + aspirin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| stent thrombosis | no data | | Cardiovascular death/MI/stent thrombosis | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | MACE | 1.02 [0.63 1.67] | p=1.00 | 0 | 2469 | 4 | Müller,CLASSICS,TOPPS,Piamsomboon, | | All cause death | no data | | Major bleeding | no data | | GUSTO severe/moderate bleeding | no data | | any bleedings | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| clopidogrel+aspirin vs aspirin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| stent thrombosis | 1.24 [0.33 4.62] | p=1.00 | 0 | 2682 | 1 | REAL-LATE, ZEST-LATE, | | Cardiovascular death/MI/stent thrombosis | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 1.41 [0.54 3.73] | p=1.00 | 0 | 2682 | 1 | REAL-LATE, ZEST-LATE, | | stroke (fatal and non fatal) | 2.23 [0.68 7.25] | p=1.00 | 0 | 2682 | 1 | REAL-LATE, ZEST-LATE, | | MACE | no data | | All cause death | 1.52 [0.75 3.07] | p=1.00 | 0 | 2682 | 1 | REAL-LATE, ZEST-LATE, | | Major bleeding | 2.97 [0.31 28.58] | p=1.00 | 0 | 2682 | 1 | REAL-LATE, ZEST-LATE, | | GUSTO severe/moderate bleeding | no data | | any bleedings | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| high-dose clopidogrel vs normal-dose clopidogrel | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| stent thrombosis | 0.62 [0.20 1.91] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | Cardiovascular death/MI/stent thrombosis | 1.01 [0.58 1.76] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | Cardiovascular death | 0.37 [0.10 1.41] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | myocardial infarction (fatal and non fatal) | 1.11 [0.58 2.10] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | stroke (fatal and non fatal) | no data | | MACE | no data | | All cause death | 0.70 [0.26 1.84] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | Major bleeding | no data | | GUSTO severe/moderate bleeding | 0.60 [0.31 1.14] | p=1.00 | 0 | 2187 | 1 | GRAVITAS, | | any bleedings | 1.17 [0.90 1.53] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
Patients with high residual platelet activity on clopidogrel: 1 trials - GRAVITAS
| high-dose clopidogrel vs normal-dose clopidogrel | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| stent thrombosis | 0.62 [0.20 1.91] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | Cardiovascular death/MI/stent thrombosis | 1.01 [0.58 1.76] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | Cardiovascular death | 0.37 [0.10 1.41] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | myocardial infarction (fatal and non fatal) | 1.11 [0.58 2.10] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | stroke (fatal and non fatal) | no data | | MACE | no data | | All cause death | 0.70 [0.26 1.84] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | Major bleeding | no data | | GUSTO severe/moderate bleeding | 0.60 [0.31 1.14] | p=1.00 | 0 | 2187 | 1 | GRAVITAS, | | any bleedings | 1.17 [0.90 1.53] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
PCI with stent placement: 5 trials - Müller - CLASSICS - TOPPS - Piamsomboon - GRAVITAS
| clopidogrel + aspirin vs ticlopidine + aspirin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| stent thrombosis | no data | | Cardiovascular death/MI/stent thrombosis | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | MACE | 1.02 [0.63 1.67] | p=1.00 | 0 | 2469 | 4 | Müller,CLASSICS,TOPPS,Piamsomboon, | | All cause death | no data | | Major bleeding | no data | | GUSTO severe/moderate bleeding | no data | | any bleedings | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| high-dose clopidogrel vs normal-dose clopidogrel | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| stent thrombosis | 0.62 [0.20 1.91] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | Cardiovascular death/MI/stent thrombosis | 1.01 [0.58 1.76] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | Cardiovascular death | 0.37 [0.10 1.41] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | myocardial infarction (fatal and non fatal) | 1.11 [0.58 2.10] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | stroke (fatal and non fatal) | no data | | MACE | no data | | All cause death | 0.70 [0.26 1.84] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | Major bleeding | no data | | GUSTO severe/moderate bleeding | 0.60 [0.31 1.14] | p=1.00 | 0 | 2187 | 1 | GRAVITAS, | | any bleedings | 1.17 [0.90 1.53] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
After revascularisation: 1 trials - AFFIRM
| clopidogrel vs | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Amputation | no data | | cardiovascular events | no data | | All cause death | no data | | Treatment related complication | no data | | Infection | no data | | Bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patient: 1 trials - CAPRIE (PAD subgroup)
| clopidogrel vs aspirin | No demonstrated result suggested myocardial infarction (fatal and non fatal) by 37% (not demonstrated) suggested Fatal MI by 38% (not demonstrated) | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Amputation | no data | | myocardial infarction (fatal and non fatal) | 0.63 [0.46 0.86] | p=0.04 | 0 | 6452 | 1 | CAPRIE (PAD subgroup), | | Vascular death | no data | | Fatal MI | 0.62 [0.43 0.88] | p=0.04 | 0 | 6452 | 1 | CAPRIE (PAD subgroup), | | Non fatal MI | 0.67 [0.37 1.22] | p=1.00 | 0 | 6452 | 1 | CAPRIE (PAD subgroup), | | Vascular events | no data | | All cause death | 0.81 [0.62 1.06] | p=1.00 | 0 | 6452 | 1 | CAPRIE (PAD subgroup), | | Fatal stroke | 0.95 [0.68 1.32] | p=1.00 | 0 | 6452 | 1 | CAPRIE (PAD subgroup), | | Non fatal stroke | 1.38 [0.55 3.43] | p=1.00 | 0 | 6452 | 1 | CAPRIE (PAD subgroup), | | Non cerebral major bleeding | no data | | Fatal bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patient: 1 trials - CAPRIE
| clopidogrel vs aspirin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | Coronary event | no data | | Fatal MI | 0.71 [0.50 1.00] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Non fatal MI | 0.85 [0.71 1.00] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | All cause death | 0.98 [0.87 1.10] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Adverse events | no data | | Major bleeding | no data | | stroke (fatal and non fatal) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 1 trials - CAPRIE
| clopidogrel vs aspirin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | Coronary event | no data | | Fatal MI | 0.71 [0.50 1.00] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Non fatal MI | 0.85 [0.71 1.00] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | All cause death | 0.98 [0.87 1.10] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Adverse events | no data | | Major bleeding | no data | | stroke (fatal and non fatal) | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patient: 1 trials - ASCET
| clopidogrel vs aspirin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| cardiovascular events | 0.90 [0.60 1.35] | p=1.00 | 0 | 1001 | 1 | ASCET, | | Cardiovascular death | no data | | Non vascular death | no data | | Non fatal MI | no data | | Non fatal stroke | no data | | Major bleeding | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
All type of patients: 6 trials - Müller - CLASSICS - TOPPS - Piamsomboon - GRAVITAS - REAL-LATE, ZEST-LATE
| clopidogrel + aspirin vs ticlopidine + aspirin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| stent thrombosis | no data | | Cardiovascular death/MI/stent thrombosis | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | no data | | stroke (fatal and non fatal) | no data | | MACE | 1.02 [0.63 1.67] | p=1.00 | 0 | 2469 | 4 | Müller,CLASSICS,TOPPS,Piamsomboon, | | All cause death | no data | | Major bleeding | no data | | GUSTO severe/moderate bleeding | no data | | any bleedings | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| clopidogrel+aspirin vs aspirin | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| stent thrombosis | 1.24 [0.33 4.62] | p=1.00 | 0 | 2682 | 1 | REAL-LATE, ZEST-LATE, | | Cardiovascular death/MI/stent thrombosis | no data | | Cardiovascular death | no data | | myocardial infarction (fatal and non fatal) | 1.41 [0.54 3.73] | p=1.00 | 0 | 2682 | 1 | REAL-LATE, ZEST-LATE, | | stroke (fatal and non fatal) | 2.23 [0.68 7.25] | p=1.00 | 0 | 2682 | 1 | REAL-LATE, ZEST-LATE, | | MACE | no data | | All cause death | 1.52 [0.75 3.07] | p=1.00 | 0 | 2682 | 1 | REAL-LATE, ZEST-LATE, | | Major bleeding | 2.97 [0.31 28.58] | p=1.00 | 0 | 2682 | 1 | REAL-LATE, ZEST-LATE, | | GUSTO severe/moderate bleeding | no data | | any bleedings | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| high-dose clopidogrel vs normal-dose clopidogrel | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| stent thrombosis | 0.62 [0.20 1.91] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | Cardiovascular death/MI/stent thrombosis | 1.01 [0.58 1.76] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | Cardiovascular death | 0.37 [0.10 1.41] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | myocardial infarction (fatal and non fatal) | 1.11 [0.58 2.10] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | stroke (fatal and non fatal) | no data | | MACE | no data | | All cause death | 0.70 [0.26 1.84] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, | | Major bleeding | no data | | GUSTO severe/moderate bleeding | 0.60 [0.31 1.14] | p=1.00 | 0 | 2187 | 1 | GRAVITAS, | | any bleedings | 1.17 [0.90 1.53] | p=1.00 | 0 | 2214 | 1 | GRAVITAS, |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
